Rnc Capital Management LLC Gilead Sciences, Inc. Transaction History

Rnc Capital Management LLC

$1.74 Billion
Q2 2024

A detailed history of Rnc Capital Management LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rnc Capital Management LLC holds 649,418 shares of GILD stock, worth $54.4 Million. This represents 2.57% of its overall portfolio holdings.

Number of Shares

649,418

Previous 626,721 3.62%

Holding current value

$54.4 Million

Previous $45.9 Million 2.94%

% of portfolio

2.57%

Previous 2.71%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $1.43 Million - $1.65 Million	22,697 Added 3.62%	649,418 $44.6 Million
Q1 2024 Aug 07, 2024	SELL	$71.58 - $87.29 $3.7 Million - $4.51 Million	-51,714 Reduced 7.62%	626,721 $45.9 Million
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $248,458 - $281,758	-3,391 Reduced 0.5%	678,435 $55 Million
Q3 2023 Dec 27, 2023	SELL	$73.94 - $80.67 $1.97 Million - $2.15 Million	-26,668 Reduced 3.76%	681,826 $51.1 Million
Q2 2023 Jul 20, 2023	BUY	$76.01 - $86.7 $115,155 - $131,350	1,515 Added 0.21%	708,494 $54.6 Million
Q1 2023 Apr 21, 2023	BUY	$77.31 - $88.08 $157,557 - $179,507	2,038 Added 0.29%	706,979 $58.7 Million
Q4 2022 Jan 10, 2023	BUY	$62.32 - $89.47 $1.17 Million - $1.69 Million	18,841 Added 2.75%	704,941 $60.5 Million
Q3 2022 Oct 18, 2022	BUY	$59.54 - $68.01 $8.68 Million - $9.92 Million	145,858 Added 27.0%	686,100 $42.3 Million
Q2 2022 Jul 22, 2022	BUY	$57.72 - $65.01 $743,318 - $837,198	12,878 Added 2.44%	540,242 $33.4 Million
Q1 2022 Jul 22, 2022	SELL	$57.92 - $72.58 $130,609 - $163,667	-2,255 Reduced 0.43%	527,364 $31.4 Million
Q4 2021 Feb 04, 2022	BUY	$64.88 - $73.64 $5.44 Million - $6.18 Million	83,870 Added 18.82%	529,619 $38.5 Million
Q3 2021 Nov 02, 2021	BUY	$67.69 - $73.03 $201,986 - $217,921	2,984 Added 0.67%	445,749 $31.1 Million
Q2 2021 Jul 20, 2021	BUY	$63.47 - $69.35 $9.93 Million - $10.8 Million	156,449 Added 54.64%	442,765 $30.5 Million
Q1 2021 Apr 26, 2021	BUY	$60.0 - $68.46 $4.48 Million - $5.11 Million	74,710 Added 35.31%	286,316 $18.5 Million
Q4 2020 Jan 13, 2021	SELL	$56.65 - $64.55 $5.87 Million - $6.69 Million	-103,618 Reduced 32.87%	211,606 $12.3 Million
Q3 2020 Dec 03, 2020	SELL	$62.1 - $78.08 $895,419 - $1.13 Million	-14,419 Reduced 4.37%	315,224 $19.9 Million
Q2 2020 Jul 23, 2020	BUY	$72.34 - $84.0 $594,056 - $689,808	8,212 Added 2.55%	329,643 $25.4 Million
Q1 2020 Apr 22, 2020	BUY	$62.63 - $80.22 $18.7 Million - $23.9 Million	298,169 Added 1281.79%	321,431 $24 Million
Q4 2019 Mar 09, 2020	BUY	$61.62 - $67.78 $978,217 - $1.08 Million	15,875 Added 214.9%	23,262 $1.51 Million
Q3 2019 Jul 22, 2020	BUY	$62.51 - $69.0 $3,750 - $4,140	60 Added 0.82%	7,387 $468,000
Q2 2019 Jul 25, 2019	SELL	$61.87 - $69.38 $44,855 - $50,300	-725 Reduced 9.0%	7,327 $495,000
Q1 2019 Apr 18, 2019	SELL	$62.53 - $70.05 $13,881 - $15,551	-222 Reduced 2.68%	8,052 $523,000
Q4 2018 Jan 15, 2019	SELL	$60.54 - $79.0 $26,698 - $34,839	-441 Reduced 5.06%	8,274 $518,000
Q3 2018 Oct 25, 2018	SELL	$71.28 - $78.92 $148,975 - $164,942	-2,090 Reduced 19.34%	8,715 $673,000
Q2 2018 Jul 20, 2018	SELL	$64.88 - $75.68 $6,488 - $7,568	-100 Reduced 0.92%	10,805 $765,000
Q1 2018 Apr 11, 2018	SELL	$72.84 - $88.8 $40,062 - $48,840	-550 Reduced 4.8%	10,905 $822,000
Q4 2017 Jan 17, 2018	SELL	$71.15 - $83.52 $1,138 - $1,336	-16 Reduced 0.14%	11,455 $821,000
Q3 2017 Oct 16, 2017	SELL	$72.11 - $85.47 $5.21 Million - $6.17 Million	-72,231 Reduced 86.3%	11,471 $929,000
Q2 2017 Aug 22, 2017	BUY	N/A	83,702	83,702 $5.92 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rnc Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rnc Capital Management LLC with notifications on news.

Account

Rnc Capital Management LLC Gilead Sciences, Inc. Transaction History